Clinical Trial Search

Primary: Change From Baseline in A1C at Week 26: Excluding Rescue Approach — -1.02; -1.08; -1.05; -1.49 Percentage — p=<0.001

Primary: Change in Plaque Index — 0.8050; 0.8959; 0.6677; 0.9891 units on a scale — p=0.0444

Primary: Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. — 42.9; 51.4; 30.4; 44 units on a scale

Primary: Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week…

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…

Primary: Birchwood Social Function Scale (BSFS) Total Score — 120; 115.8; 120.8; 127 units on a scale

Primary: Stimulated Acute Tear Production — 17.28; 7.92 Scores on a scale

Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score

Primary: Disease-specific Survival (DSS) (10-year Rates Reported) — 95; 96 percentage of participants — p=0.45

Primary: Number of Participants Experiencing Serious and Non Serious Adverse Events — 19 Participants

Primary: Change From Baseline to Last Assessment in Treatment Period in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -13.1 units on a scale

Primary: Number of Microscopically Confirmed Episodes of Infusion Set Occlusions — 0; 0 Episodes

Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL — 66.7 Percentage of Participants

Primary: Number of Grade 3 or Higher Adverse Events — 0 Events